040-000-182 Orlistat

SKU: 040-000-182 Category:
Get A Quote






  I would like to join the mailing list to receive updates from Stanford Chemicals.
*: e-mail address with your company's domain name is preferred. Otherwise, we may not be able to process your inquiry.

Category Pharmaceutical raw materials
Synonym (−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-(2S,3S)-3-hexyl-4-oxo-2-oxetanylmethyldodecyl ester, Ro-18-0647
CAS No. 96829-58-2
Chemical Formula C29H53NO5
Molecular Weight 495.73
Appearance White Powder
Package Customized Package.
Packaging DRUM, Plastic Container
Grade Cosmetic grade
Assay ≥98%
Description

Description

Product Name: Orlistat
Synonyms: (-)-Tetrahydrolipstatin Orlipastat Orlipastatum [INN-Latin] Tetrahydrolipstatin, (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate
CAS: 96829-58-2
MF: (C14H22NNaO11)n
Appearance: White powder
Standard: purity >99%

 Orlistat

Orlistat Introduction:

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass. After orlistat was stopped, a significant number of subjects regained weight—up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

Orlistat Functions:

Orlistat combined with a low-calorie diet is suitable for long-term treatment of obese and overweight patients, including those who have developed risk factors related to obesity. It has the effect of long-term weight control (reduces weight, maintains weight, and prevents rebound). It can also reduce the risk factors related to obesity and the incidence of other diseases related to obesity, including hypercholesterolemia and type 2 diabetes.

Biological Activity

Hypolipemic pancreatic, gastric, and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A2, liver esterase, trypsin, and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G1/S boundary in vitro. Prevents the absorption of approximately one-third of fat from food and exhibits progastrokinetic, antiobesity, and antihypercholesterolemic activity in vivo.

Related products: Cilostazol, Nicotinamide mononucleotide, Acarbose